Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery

被引:43
作者
Gautam, Ajay [1 ]
Koshkina, Nadezhda [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA
关键词
D O I
10.2174/1568009033481912
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Paclitaxel (PTX, Taxol) has revolutionized cancer treatment in the past decade and is recognized as one of the biggest advances in oncology medicine. In spite of the good clinical efficacy shown by PTX, there is still a growing need to achieve better safety and pharmacokinetic profile of PTX in patients. The standard delivery modalities of intravenous infusion result in multiple side effects, and targeting of the drug to specific areas within the body can result in better efficacy and lower toxicity. Aerosol delivery of therapeutic agents has the potential of localizing the drugs specifically to the lung tissue, with a comparable or better pharmacokinetics as compared to intravenous, oral or intraperitoneal delivery. Aerosol delivery of PTX has not been studied extensively, however, it holds immense potential for improving the efficacy against lung tumors. Early pre-clinical studies in mice and dogs have shown good promise, both for pharmacokinetics of PTX, safety and efficacy in lung cancer models. This review looks at the still developing approach of aerosol delivery of PTX for lung cancer, documents the progress so far and the future directions that can bring this approach to clinical reality.
引用
收藏
页码:287 / 296
页数:10
相关论文
共 63 条
[1]  
Anderson PM, 1999, CLIN CANCER RES, V5, P2316
[2]  
Avramis VI, 1998, ANTICANCER RES, V18, P2327
[3]   Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53 [J].
Bacus, SS ;
Gudkov, AV ;
Lowe, M ;
Lyass, L ;
Yung, Y ;
Komarov, AP ;
Keyomarsi, K ;
Yarden, Y ;
Seger, R .
ONCOGENE, 2001, 20 (02) :147-155
[4]  
BISSERY MC, 1991, CANCER RES, V51, P4845
[5]   Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer [J].
Breathnach, OS ;
Kasturi, V ;
Kaye, F ;
Herscher, L ;
Georgiadis, MS ;
Edison, M ;
Schuler, BS ;
Pizzella, P ;
Steinberg, SM ;
O'Neil, K ;
Johnson, BE .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (03) :269-273
[6]  
Britten CD, 2000, CLIN CANCER RES, V6, P3459
[7]   Expression of protein kinase C β1 confers resistance to TNFα- and paclitaxel-induced apoptosis in HT-29 colon carcinoma cells [J].
Cesaro, P ;
Raiteri, E ;
Démoz, M ;
Castino, R ;
Baccino, FM ;
Bonelli, G ;
Isidoro, C .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (02) :179-184
[8]   Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-κB- and AP-1-dependent mechanism [J].
Collins, TS ;
Lee, LF ;
Ting, JPY .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (02) :78-84
[9]  
EISEMAN JL, 1994, CANCER CHEMOTH PHARM, V34, P465, DOI 10.1007/BF00685656
[10]  
Fidias P, 2001, CLIN CANCER RES, V7, P3942